Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Wednesday, September 4, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. (Nasdaq: DTIL) will participate in the H.C. Wainwright 26th Annual Global Healthcare Conference. The company focuses on advanced gene editing using its proprietary ARCUS platform, which enables sophisticated gene edits. This participation highlights the company's commitment to advancing gene editing therapies.
Price reaction · baseline $10.4 (2024-09-03 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent healthcare conference.
  • Showcases Precision BioSciences' innovative ARCUS platform.
  • Potential for increased visibility and networking opportunities.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Sep. 4, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, gene insertion, and gene

Frequently Asked Questions

What is Precision BioSciences known for?

Precision BioSciences specializes in advanced gene editing using its proprietary ARCUS platform.

When is the H.C. Wainwright conference?

The H.C. Wainwright 26th Annual Global Healthcare Conference is scheduled for September 2024.

What therapies does Precision BioSciences develop?

The company develops in vivo gene editing therapies for gene elimination, insertion, and more.

Why is the conference important for Precision BioSciences?

Participation increases visibility and networking opportunities for the company.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences ARCUS platform gene editing H.C. Wainwright healthcare conference
Last updated: Sep 4, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →